65 related articles for article (PubMed ID: 15834134)
1. Prostaglandin E2 receptors EP2 and EP4 are down-regulated during differentiation of mouse osteoclasts from their precursors.
Kobayashi Y; Take I; Yamashita T; Mizoguchi T; Ninomiya T; Hattori T; Kurihara S; Ozawa H; Udagawa N; Takahashi N
J Biol Chem; 2005 Jun; 280(25):24035-42. PubMed ID: 15834134
[TBL] [Abstract][Full Text] [Related]
2. Metabolic regulation by prostaglandin E
Robb CT; Zhou Y; Felton JM; Zhang B; Goepp M; Jheeta P; Smyth DJ; Duffin R; Vermeren S; Breyer RM; Narumiya S; McSorley HJ; Maizels RM; Schwarze JKJ; Rossi AG; Yao C
Allergy; 2023 Mar; 78(3):714-730. PubMed ID: 36181709
[TBL] [Abstract][Full Text] [Related]
3. Prostaglandin E
Goepp M; Crittenden S; Zhou Y; Rossi AG; Narumiya S; Yao C
Immunology; 2021 Dec; 164(4):777-791. PubMed ID: 34529833
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological evidence that the inhibitory effects of prostaglandin E2 are mediated by the EP2 and EP4 receptors in human neutrophils.
Lavoie JC; Simard M; Kalkan H; Rakotoarivelo V; Huot S; Di Marzo V; Côté A; Pouliot M; Flamand N
J Leukoc Biol; 2024 May; 115(6):1183-1189. PubMed ID: 38345417
[TBL] [Abstract][Full Text] [Related]
5. Design of Dual EP2/EP4 Antagonists through Scaffold Merging of Selective Inhibitors.
Corminboeuf O; Diethelm S; Zumbrunn C; Lyothier I; Niggli N; Gnerre C; Jeay S; Lehembre F; Boss C
ChemMedChem; 2024 Jan; 19(2):e202300606. PubMed ID: 37983645
[TBL] [Abstract][Full Text] [Related]
6. EP2 and EP4 blockade prevents tumor-induced suppressive features in human monocytic myeloid-derived suppressor cells.
Cuenca-Escalona J; Subtil B; Garcia-Perez A; Cambi A; de Vries IJM; Flórez-Grau G
Front Immunol; 2024; 15():1355769. PubMed ID: 38343540
[TBL] [Abstract][Full Text] [Related]
7. PGE2-EP4 signaling steers cDC2 maturation toward the induction of suppressive T-cell responses.
Cuenca-Escalona J; Flórez-Grau G; van den Dries K; Cambi A; de Vries IJM
Eur J Immunol; 2024 Mar; 54(3):e2350770. PubMed ID: 38088451
[TBL] [Abstract][Full Text] [Related]
8. Targeting EP2 Receptor for Drug Discovery: Strengths, Weaknesses, Opportunities, and Threats (SWOT) Analysis.
Ganesh T
J Med Chem; 2023 Jul; 66(14):9313-9324. PubMed ID: 37458373
[TBL] [Abstract][Full Text] [Related]
9. Complementary roles of EP2 and EP4 receptors in malignant glioma.
Qiu J; Li Q; Li J; Zhou F; Sang P; Xia Z; Wang W; Wang L; Yu Y; Jiang J
Br J Pharmacol; 2023 Oct; 180(20):2623-2640. PubMed ID: 37232020
[TBL] [Abstract][Full Text] [Related]
10. EP4 Receptor Conformation Sensor Suited for Ligand Screening and Imaging of Extracellular Prostaglandins.
Kurz M; Ulrich M; Bittner A; Scharf MM; Shao J; Wallenstein I; Lemoine H; Wettschureck N; Kolb P; Bünemann M
Mol Pharmacol; 2023 Sep; 104(3):80-91. PubMed ID: 37442628
[TBL] [Abstract][Full Text] [Related]
11. Effects of selective prostaglandins E2 receptor agonists on cultured calvarial murine osteoblastic cells.
Alander CB; Raisz LG
Prostaglandins Other Lipid Mediat; 2006 Dec; 81(3-4):178-83. PubMed ID: 17085326
[TBL] [Abstract][Full Text] [Related]
12. PGE
Lacher SB; Dörr J; de Almeida GP; Hönninger J; Bayerl F; Hirschberger A; Pedde AM; Meiser P; Ramsauer L; Rudolph TJ; Spranger N; Morotti M; Grimm AJ; Jarosch S; Oner A; Gregor L; Lesch S; Michaelides S; Fertig L; Briukhovetska D; Majed L; Stock S; Busch DH; Buchholz VR; Knolle PA; Zehn D; Dangaj Laniti D; Kobold S; Böttcher JP
Nature; 2024 May; 629(8011):417-425. PubMed ID: 38658748
[TBL] [Abstract][Full Text] [Related]
13. Role of prostaglandin E
Lin ZQ; Yao Y; Zhang YF; Zhang XY; Guan YF
Sheng Li Xue Bao; 2024 Apr; 76(2):329-340. PubMed ID: 38658381
[TBL] [Abstract][Full Text] [Related]
14. Prostaglandin E2 and F2α Alter Expression of Select Cholesteryl Esters and Triacylglycerols Produced by Human Meibomian Gland Epithelial Cells.
Ziemanski JF; Wilson L; Barnes S; Nichols KK
Cornea; 2022 Jan; 41(1):95-105. PubMed ID: 34483274
[TBL] [Abstract][Full Text] [Related]
15. Edition of Prostaglandin E2 Receptors EP2 and EP4 by CRISPR/Cas9 Technology in Equine Adipose Mesenchymal Stem Cells.
Mançanares ACF; Cabezas J; Manríquez J; de Oliveira VC; Wong Alvaro YS; Rojas D; Navarrete Aguirre F; Rodriguez-Alvarez L; Castro FO
Animals (Basel); 2020 Jun; 10(6):. PubMed ID: 32585798
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of CD36-dependent phagocytosis by prostaglandin E2 contributes to the development of endometriosis.
Chuang PC; Lin YJ; Wu MH; Wing LY; Shoji Y; Tsai SJ
Am J Pathol; 2010 Feb; 176(2):850-60. PubMed ID: 20035060
[TBL] [Abstract][Full Text] [Related]
17. Prostaglandin E
Crittenden S; Goepp M; Pollock J; Robb CT; Smyth DJ; Zhou Y; Andrews R; Tyrrell V; Gkikas K; Adima A; O'Connor RA; Davies L; Li XF; Yao HX; Ho GT; Zheng X; Mair A; Vermeren S; Qian BZ; Mole DJ; Gerasimidis K; Schwarze JKJ; Breyer RM; Arends MJ; O'Donnell VB; Iredale JP; Anderton SM; Narumiya S; Maizels RM; Rossi AG; Howie SE; Yao C
Sci Adv; 2021 Feb; 7(7):. PubMed ID: 33579710
[TBL] [Abstract][Full Text] [Related]
18. Prostaglandin E2 promotes Th17 differentiation induces corneal epithelial cell apoptosis and participates in the progression of dry eye.
Zhang W; Yin J; Deng Y; Gong Y; Sun X; Chen J
Arch Biochem Biophys; 2024 Jan; 751():109823. PubMed ID: 37984760
[TBL] [Abstract][Full Text] [Related]
19. Prostaglandin E
Bryson TD; Harding P
Biochem Pharmacol; 2023 Nov; 217():115813. PubMed ID: 37722627
[TBL] [Abstract][Full Text] [Related]
20. The Signaling Pathway of PGE
An Y; Yao J; Niu X
Mediators Inflamm; 2021; 2021():9087816. PubMed ID: 34867083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
